Agios Q1 PYRUKYND revenue $8.7M; PDUFA Sept 7 for thalassemia; net loss $89.3M

AGIOS PHARMACEUTICALS, INC.

2025-Q1 EPS reported -$1.55 revenue$8,726,000

PYRUKYND net revenue $8.7M in Q1 2025 vs $8.2M in Q1 2024; 136 patients on therapy.
FDA accepted sNDA for thalassemia with PDUFA goal date September 7, 2025; no advisory committee planned.
Phase 3 RISE UP in sickle cell disease topline results expected late 2025; potential US launch in 2026.
Net loss $89.3M in Q1 2025 vs $81.5M in Q1 2024; cash and securities $1.4B as of March 31, 2025.
Krishnan Viswanadhan appointed Chief Corporate Development and Strategy Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.